Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema

Journal of Allergy and Clinical Immunology

Volumn 126, Issue 4, 2010, Pages

  Zuraw, Bruce ^a   Cicardi, Marco ^b   Levy, Robyn J ^c   Nuijens, Jan H ^d   Relan, Anurag ^d   Visscher, Sonja ^d   Haase, Gerald ^e   Kaufman, Leonard ^f   Hack, C Erik ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c Family Allergy and Asthma Center   (United States)

^d Pharming Group NV   (Netherlands)

^e Haase Consultancy Services Ltd   (United Kingdom)

^f Veeda Clinical Research   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

angioedema; attack; efficacy; HAE; recombinant human C1 inhibitor; safety

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; PLACEBO; RECOMBINANT PROTEIN; SODIUM CHLORIDE;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 77957792655     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.07.021     Document Type: Article

References (34)

1. A. Bygum Hereditary angio-edema in Denmark: a nationwide survey Br J Dermatol 161 2009 1153 1158
2. B.J. Zuraw Hereditary angioedema N Engl J Med 359 2008 1027 1036
3. E. Pappalardo, S. Caccia, C. Suffritti, A. Tordai, L.C. Zingale, and M. Cicardi Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates Mol Immunol 45 2008 3536 3544
4. U.C. Nzeako, E. Frigas, and W.J. Tremaine Hereditary angioedema: a broad review for clinicians Arch Intern Med 161 2001 2417 2429
5. F.S. Rosen, C.A. Alper, J. Pensky, M.R. Klemperer, and V.H. Donaldson Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema J Clin Invest 50 1971 2143 2149
6. A. Agostoni, E. Aygören-Pürsün, K.E. Binkley, A. Blanch, K. Bork, and L. Bouillet Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 Esterase Inhibitor Deficiency Workshop and beyond J Allergy Clin Immunol 114 2004 S51 S131
7. A. Agostoni, and M. Cicardi Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients Medicine (Baltimore) 71 1992 206 215
8. M.M. Frank, J.A. Gelfand, and J.P. Atkinson Hereditary angioedema: the clinical syndrome and its management Ann Intern Med 84 1976 580 593
9. K. Bork, K. Siedlecki, S. Bosch, R.E. Schopf, and W. Kreuz Asphyxiation by laryngeal edema in patients with hereditary angioedema Mayo Clin Proc 75 2000 349 354
10. J. Nussberger, M. Cugno, and M. Cicardi Bradykinin-mediated angioedema N Engl J Med 347 2002 621 622
11. E.D. Han, R.C. MacFarlane, A.N. Mulligan, J. Scafidi, and A.E. Davis III Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor J Clin Invest 109 2002 1057 1063
12. M.J. Prematta, T. Prematta, and T.J. Craig Treatment of hereditary angioedema with plasma-derived C1 inhibitor Therapeutics and clinical risk management 4 2008 975 982
13. T.J. Craig, R.J. Levy, R.L. Wasserman, A.K. Bewtra, D. Hurewitz, and K. Obtułowicz Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks J Allergy Clin Immunol 124 2009 801 808
14. A.T. Waytes, F.S. Rosen, and M.M. Frank Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate N Engl J Med 334 1996 1630 1634
15. M. Kunschak, W. Engl, F. Maritsch, F.S. Rosen, G. Eder, and G. Zerlauth A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema Transfusion 38 1998 540 549
16. J.H. Nuijens, and C.E. Hack Recombinant C1 inhibitor J Allergy Clin Immunol 114 2004 S100 S104
17. M.B.A. Van Doorn, J. Burggraaf, T. van Dam, A. Eerenberg, M. Levi, and C.E. Hack A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema J Allergy Clin Immunol 116 2005 876 883
18. G. Choi, M.R. Soeters, H. Farkas, L. Varga, K. Obtulowicz, and B. Bilo Recombinant human C1-inhibitor in the treatment of acute angioedema attack Transfusion 47 2007 1028 1032
19. Nuijens JH, Verdonk R, Resink T, Visscher S, van Doorn M, Choi G, et al. Open-label studies of recombinant human C1 Inhibitor (rhC1INH) in patients with acute attacks of hereditary angioedema [abstract]. Available at: http://www.haenet.hu/new/abstractbook.pdf. Accessed August 31, 2010.
20. I.G. Wagenaar-Bos, C. Drouet, E. Aygören-Pürsün, K. Bork, C. Bucher, and A. Bygum Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations J Immunol Meth 338 2008 14 20
21. K. Bork, J. Frank, B. Grundt, P. Schlattmann, J. Nussberger, and W. Kreuz Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (icatibant) J Allergy Clin Immunol 119 2007 1497 1503
22. K.H. Todd, K.G. Funk, J.P. Funk, and R. Bonacci Clinical significance of reported changes in pain severity Emerg Med 27 1996 485 489
23. E.J. Gallagher, P.E. Bijur, C. Latimer, and W. Silver Reliability and validity of a visual analog scale for acute abdominal pain in the ED Am J Emerg Med 20 2002 287 290
24. European Medicines Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Available at: http://www.ispor.org/workpaper/EMEA-HRQL- Guidance.pdf. Accessed July 27, 2005.
25. Food and Drug Administration Guidance for industry: patient-reported outcomes: use in medical product development to support labeling claims: draft guidance Health Qual Life Outcomes 4 2006 79
26. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research; 2009. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed December 2009.
27. K. Bork, and S.E. Barnstedt Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema Arch Intern Med 161 2001 714 718
28. K. Bork, P. Staubach, and J. Hardt Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema Allergy 63 2008 751 757
29. K. Bork, G. Meng, P. Staubach, and J. Hardt Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema Transfusion 45 2005 1774 1784
30. T. Bowen, M. Cicardi, H. Farkas, K. Bork, W. Kreuz, and L. Zingale Canadian 2003 International Consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema J Allergy Clin Immunol 114 2004 629 637
31. I. Martinez-Saguer, E. Rusicke, E. Aygören-Pürsün, N. von Hentig, T. Klingebiel, and W. Kreuz Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study Transfusion 50 2010 354 360
32. M. Cicardi, L.C. Zingale, A. Zanichelli, D.L. Deliliers, and S. Caccia The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema Expert Opin Pharmacother 8 2007 3173 3181
33. B. Zuraw, P. Busse, M. White, J. Jacobs, W. Lumry, and J. Baker Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema N Engl J Med 363 2010 513 522
34. J. Nuijens, R. Verdonk, B. Giannetti, S. Visscher, M. van Doorn, and T. Resink Clinical studies of recombinant human C1 inhibitor (rhC1INH) in patients with acute attacks of hereditary angioedema [abstract] J Allergy Clin Immunol 115 suppl 2008 S202